ClinicalTrials.gg
RecruitingNCT07138196Updated Dec 30, 2025

A Study to Evaluate Adrixetinib (Q702) in Adults With Active Chronic Graft-Versus-Host Disease

A Phase 1 interventional study of Adrixetinib in Chronic Graft-Versus-Host Disease, sponsored by Qurient Co., Ltd.. Recruiting at 8 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-30.

Sponsored by Qurient Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 60 studies in Bronchiolitis Obliterans Syndrome with a site in Spain — 11 open to participants now, 17 under way, 6 of them phase 3. Bronchiolitis Obliterans Syndrome · Spain.

Planned enrollment
50th of 56
18 · median 129
Started
2025
with 4 others
Phase 1
2 of 60
1 open now
Primary completion
2029-10
later than 14 of 16 live
Registered
55th of 60
by date

Among the 60 studies in Bronchiolitis Obliterans Syndrome with a site in Spain, this one is the 50th largest by planned enrollment of the 56 interventional ones that give a count, is one of 5 that started in 2025, is one of 2 in phase 1, reaches primary completion later than 14 of the 16 other live ones, and was the 55th registered.

Bronchiolitis Obliterans Syndrome

714 studies on the registry are indexed under Bronchiolitis Obliterans Syndrome; 128 are open to participants now.

Browse Bronchiolitis Obliterans Syndrome studies →

Open to participants now

11 of the 60 studies in Bronchiolitis Obliterans Syndrome with a site in Spain are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 100 Bronchiolitis Obliterans Syndrome studies recruiting now, 45 (45%) set no upper age limit and 45 (45%) stop at 75 or younger; 25 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Bronchiolitis Obliterans Syndrome with a site in Spain, or all of them as a file.
02

Study summary

Open-label, dose escalation study to evaluate safety, tolerability pharmacokinetic and pharmacodynamic activity, and efficacy of Adrixetinib (Q702) in subjects with relapsed or refractory active chronic graft-versus-host disease (cGVHD).

03

Conditions studied

  • Chronic Graft-Versus-Host Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects who are HSCT recipients with moderate or severe active cGVHD requiring systemic immune suppression.
  2. Subjects with active cGVHD who have progressed after all available standard of care treatments.
  3. Subject must have documented progressive disease as defined by the NIH 2014 consensus criteria, in terms of either organ specific algorithm or global assessment, or active, symptomatic cGVHD for which the treating physician believes that a new is required.
  4. Adequate organ and bone marrow functions.
  5. Performance Scale of ≥ 60.

Exclusion criteria

Exclusion Criteria:

  1. Exposure to CSF1R inhibitor therapy for any indication after transplant.
  2. Any evidence (histologic, cytogenetic, molecular, hematologic, or mixed) of relapse of the underlying cancer.
  3. Diagnosed with another (other than malignancy for which transplant was performed) within 3 years of enrollment.
  4. Female subject who is pregnant or breastfeeding.
  5. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    Adrixetinib (Q702)

    Escalating doses of adrixetinib in 28 day cycles.

    Drug: Adrixetinib

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants with Dose-Limiting Toxicities (DLTs)

    DLTs assessed for each dose level

    Time frame: Cycle 1 (28 Days)

  2. Number of Participants with Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs)

    AEs and SAEs assessed for each dose level.

    Time frame: Cycle 1 (28 Days)

Secondary outcomes

  1. Pharmacokinetics (PK)

    Maximum Observed Plasma Concentration (Cmax), area under the curve AUC of Q702 and its primary metabolites

    Time frame: Estimated up to Cycle 1 (28 Days)

Other outcomes

  1. Objective Response Rate (ORR)

    Proportion of subjects with CR or PR by Cycle 7 Day 1 using Organ-specific response rate based on 2014 NIH Consensus Development Project on Criteria for Clinical Trials in cGVHD

    Time frame: Cycle 7 Day 1 (One Cycle is 28 Days)

  2. Duration of Response (DOR)

    DOR defined as the time from best response of PR or CR until documented progression of cGVHD, start of new therapy, or death for any reason

    Time frame: First CR or PR until documented PD, start of new therapy or death (Estimated up to 24 months)

  3. Failure-Free Survival (FFS)

    FFS is defined as the time from study enrollment (first date of Q702 treatment) to addition of another systemic therapy for cGVHD, relapse of underlying malignancy, or death whichever is earlier.

    Time frame: Baseline to, whichever occurs first of, PD, Addition of Systemic Immune Suppressive Therapy, or Death due to Any Cause (Estimated up to 24 months)

07

Study locations

8 of 8 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Oct 2029, 46 months after the start.

Of 22 phase 1 interventional studies under Bronchiolitis Obliterans Syndrome, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 65. This study's planned 46 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2025
First posted
Aug 22, 2025
StartActual
Dec 23, 2025
Primary completionEst.
Oct 23, 2029
CompletionEst.
Oct 31, 2029
Last update
Dec 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07138196
Lead sponsor
Qurient Co., Ltd.
Responsible party
Sponsor
First posted
Aug 22, 2025
Start date
Dec 23, 2025
Primary completion
Oct 23, 2029 (estimated)
Completion
Oct 31, 2029 (estimated)
Last update
Dec 30, 2025

Study contacts

Qurient Clinical Trial Information
Contact
clinicaltrial_info@qurient.com
+82-31-8060-1610

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adrixetinib

Start the discussion